Phlegmasia cerulea dolens is a limb-threatening form of deep venous thrombosis and should be treated aggressively. The authors report a patient who presented with iliocaval and femoral deep venous thrombosis and posed an additional therapeutic challenge based on a recent history of heparin-induced thrombocytopenia. Catheter-directed pharmacologic thrombolysis and balloon venoplasty were applied in treatment. The direct thrombin inhibitor argatroban was used in place of heparin for concurrent anticoagulation. This multimodality endovascular approach (chemical and mechanical interventions) was successful in relieving the venous occlusion and salvaging the limb, while maintaining appropriate treatment for heparin-induced thrombocytopenia.
Centeno RF, Nguyen AH, Ketterer C, et al: An alternative approach: Antegrade catheter-directed thrombolysis in a case of phlegmasia cerulea dolens. Am Surg65:229-231, 1999.
3.
Augustinos P, Ouriel K: Invasive approaches to treatment of venous thromboembolism. Circulation110:I27-34, 2004.
4.
Patel NH, Plorde JJ, Meissner M: Catheter-directed thrombolysis in the treatment of phlegmasia cerulea dolens. Ann Vasc Surg12:471-475, 1998.
5.
Sullivan VV, Wolk SW, Lampman RM, et al: Upper extremity venous gangrene following coronary artery bypass. A case report and review of the literature. J Cardiovasc Surg (Torino)42:551-554, 2001.
6.
Hood DB, Weaver FA, Modrall JG, et al: Advances in the treatment of phlegmasia cerulea dolens. Am J Surg166:206-210, 1993.
7.
Bird RL, Hamilton G: Treatment options for phlegmasia cerulea dolens. J Vasc Surg21:998-999, 1995.
8.
Veal JR, Dugan TJ, Jamison WL, et al: Acute massive venous occlusion of the lower extremities. Surgery29:355-364, 1951.
9.
Martin P: Phlegmasia caerulea dolens. Br Med J4850:1351-1353, 1953.
10.
Qvarfordt P, Eklof B, Ohlin P: Intramuscular pressure in the lower leg in deep vein thrombosis and phlegmasia cerulae dolens. Ann Surg197:450-453, 1983.
11.
Baldwin ZK, Comerota AJ, Schwartz LB: Catheter-directed thrombolysis for deep venous thrombosis. Vasc Endovascular Surg38:1-9, 2004.
12.
AbuRahma AF, Perkins SE, Wulu JT, et al: Iliofemoral deep vein thrombosis: Conventional therapy versus lysis and percutaneous transluminal angioplasty and stenting. Ann Surg233:752-760, 2001.
13.
Juhan CM, Alimi YS, Barthelemy PJ, et al: Late results of iliofemoral venous thrombectomy. J Vasc Surg25:417-422, 1997.
14.
Paquet KJ, Popov S, Egli H: [Guidelines and results of consequent fibrinolytic therapy in phlegmasia cerulea dolens]. Dtsch Med Wochenschr95:903-904, 1970.
15.
Ott P, Eldrup E, Oxholm P, et al: Streptokinase therapy in the routine management of deep venous thrombosis in the lower extremities. A retrospective study of phlebographic results and therapeutic complications. Acta Med Scand219:295-300, 1986.
16.
Wlodarczyk ZK, Gibson M, Dick R, et al: Low-dose intra-arterial thrombolysis in the treatment of phlegmasia caerulea dolens. Br J Surg81:370-372, 1994.
17.
Sharafuddin MJ, Sun S, Hoballah JJ, et al: Endovascular management of venous thrombotic and occlusive diseases of the lower extremities. J Vasc Interv Radiol14:405-423, 2003.
18.
Mewissen MW, Seabrook GR, Meissner MH, et al: Catheter-directed thrombolysis for lower extremity deep venous thrombosis: Report of a national multicenter registry. Radiology211:39-49, 1999.
19.
Comerota AJ, Throm RC, Mathias SD, et al: Catheterdirected thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg32:130-137, 2000.
20.
Laiho MK, Oinonen A, Sugano N, et al: Preservation of venous valve function after catheter-directed and systemic thrombolysis for deep venous thrombosis. Eur J Vasc Endovasc Surg28:391-396, 2004.
21.
Mewissen MW: Catheter-directed thrombolysis for lower extremity deep vein thrombosis. Tech Vasc Interv Radiol4:111-114, 2001.
22.
Elsharawy M, Elzayat E: Early results of thrombolysis vs anticoagulation in iliofemoral venous thrombosis. A randomised clinical trial. Eur J Vasc Endovasc Surg24:209-214, 2002.
23.
Ouriel K, Gray B, Clair DG, et al: Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol11:295-298, 2000.
24.
Grunwald MR, Hofmann LV: Comparison of urokinase, alteplase, and reteplase for catheter-directed thrombolysis of deep venous thrombosis. J Vasc Interv Radiol15:347-352, 2004.
25.
Zarich SW, Kowalchuk GJ, Weaver WD, et al: Sequential combination thrombolytic therapy for acute myocardial infarction: Results of the Pro-Urokinase and t-PA Enhancement of Thrombolysis (PATENT) trial. J Am Coll Cardiol26:374-379, 1995.
26.
Vedantham S, Vesely TM, Sicard GA, et al: Pharmacomechanical thrombolysis and early stent placement for iliofemoral deep vein thrombosis. J Vasc Interv Radiol15:565-574, 2004.
27.
Verhaeghe R, Maleux G: Endovascular local thrombolytic therapy of iliofemoral and inferior caval vein thrombosis. Semin Vasc Med1:123-128, 2001.
28.
Greinacher A: The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparininduced thrombocytopenia. Semin Thromb Hemost30:315-327, 2004.
29.
Nikolsky E, Dangas GD: Percutaneous interventions in patients with immune-mediated heparin-induced thrombocytopenia. Semin Thromb Hemost30:305-314, 2004.
30.
Rauova L, Poncz M, McKenzie SE, et al: Ultralarge complexes of heparin and PF4 are central to the pathogenesis of heparin-induced thrombocytopenia. Blood105:131-138, 2004.
31.
Chong BH: Heparin-induced thrombocytopenia. Aust NZ J Med22:145-152, 1992.
32.
Warkentin TE, Greinacher A: Heparin-induced thrombocytopenia: Recognition, treatment, and prevention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest126:311S-337S, 2004.
